(AOF) – Genomic Vision, a biotechnology company specializing in the analysis and control of genome modifications, has announced the issue of the second tranche of bonds convertible into shares with stock warrants (Ocabsa) for a net amount of 1.92 million euros. The gross proceeds of this second tranche is 2 million euros.
In May 2022, Genomic Vision announced the signing of an issue contract with Winance with a view to setting up a financing line by issuing bonds convertible into ordinary shares, to each of which a subscription warrant will be attached. shares for a maximum total net amount of 28.8 million euros (30 million nominal value).
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.